World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
85284
World Ranking
3269
National Ranking
1804

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

William Pao is affiliated with Roche in the United States and has a research focus primarily in the field of Medicine, with notable contributions to Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Cancer Research, and Public Health.

Their research topics cover a range of areas, including:

  • Long-Term Effects of COVID-19
  • COVID-19 and healthcare impacts
  • Health, Environment, Cognitive Aging
  • Lung Cancer Treatments and Mutations
  • Cancer therapeutics and mechanisms
  • Lung Cancer Research Studies
  • Flow Measurement and Analysis

Among the recent papers authored or co-authored by William Pao are:

  • "The NIH-led research response to COVID-19" (2023), published in Science
  • "Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib" (2022), published in Journal of Medicinal Chemistry
  • "Flow Regime Identification in Gas-Liquid Two-Phase Flow in Horizontal Pipe by Deep Learning" (2022), published in Journal of Advanced Research in Applied Sciences and Engineering Technology
  • "Elucidating the Cell Surfaceome to Accelerate Cancer Drug Development" (2024), published in Cancer Discovery
  • "Paradigms for the development of transformative medicines-lessons from the EGFR story" (2022), published in Annals of Oncology

Their frequent co-authors include:

  • Yvonne A. Nagel
  • Kwok-Kin Wong
  • Roman K. Thomas
  • Lu Wang
  • Francis S. Collins

William Pao's work has appeared in several key scientific venues with multiple publications in areas related to cancer and medicine, including:

  • Cancer Discovery
  • Science
  • Journal of Medicinal Chemistry
  • Journal of Advanced Research in Applied Sciences and Engineering Technology
  • Annals of Oncology

Throughout their career, William Pao has received recognition such as membership in the Association of American Physicians. The research focus and publication record indicate engagement with therapeutic strategies and mechanisms in oncology as well as the application of advanced methodologies such as deep learning in flow measurement and analysis.

Best Publications

  • EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

    William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty

  • Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Somatic mutations affect key pathways in lung adenocarcinoma

    Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis

  • Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

    Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

    Darren A.E. Cross;Susan E. Ashton;Serban Ghiorghiu;Cath Eberlein

  • Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

    Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez

  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

    James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely

  • KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • New driver mutations in non-small-cell lung cancer

    William Pao;Nicolas Girard

  • Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer

    William Pao;Juliann Chmielecki

  • Characterizing the cancer genome in lung adenocarcinoma

    Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Acquired resistance to TKIs in solid tumours: learning from lung cancer

    D. Ross Camidge;William Pao;Lecia V. Sequist

  • Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

    Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

  • Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

    Marissa N. Balak;Yixuan Gong;Gregory J. Riely;Romel Somwar

  • Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    David Jackman;William Pao;Gregory J. Riely;Jeffrey A. Engelman

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Maureen F. Zakowski
Maureen F. Zakowski Icahn School of Medicine at Mount Sinai
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center
Roman K. Thomas
Roman K. Thomas University of Cologne
Katerina Politi
Katerina Politi Yale University
Zhongming Zhao
Zhongming Zhao The University of Texas Health Science Center at Houston
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine often starts with an MD, but there are many related fields worth exploring. Nursing is a popular option, and for students looking to avoid extra entrance hurdles, some nursing schools that don't require teas or hesi exams can streamline your entry into this rewarding profession.

For those interested in leadership roles within healthcare, pursuing an accelerated healthcare administration degree online can open doors to management positions much faster than traditional routes.

Registered nurses aiming to advance their careers can benefit from adn to msn bridge programs. These bridge pathways offer a streamlined transition to advanced practice, enabling higher earning potential and broader responsibilities.

Another growing field in healthcare is nutrition. Earning a degree through one of the best online nutrition programs equips students to make a significant impact on public health and wellness.

Exploring these online programs can diversify your skills and help you find the right career pathway in the expansive healthcare sector.

Best Scientists Citing William Pao

Trending Scientists